Federated Hermes, Inc. Mirati Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

$42.5 Billion
Q1 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$41.99 - $62.38 $60,465 - $89,827	1,440 New	1,440 $84,000
Q4 2022 Feb 13, 2023	SELL	$41.27 - $98.62 $10.7 Million - $25.7 Million	-260,245 Reduced 99.99%	25 $1,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $290,717 - $423,616	-4,886 Reduced 1.84%	260,270 $18.2 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $232,962 - $527,735	5,949 Added 2.3%	265,156 $17.8 Million
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $27,219 - $54,198	359 Added 0.14%	259,207 $21.3 Million

Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $13.7 Million - $19.7 Million	103,448 Added 66.57%	258,848 $38 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $92,491 - $124,214	700 Added 0.45%	155,400 $27.5 Million
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $308,016 - $384,442	-2,139 Reduced 1.36%	154,700 $25 Million
Q1 2021 May 13, 2021	SELL	$158.92 - $221.61 $13.5 Million - $18.9 Million	-85,113 Reduced 35.18%	156,839 $26.9 Million
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $4.9 Million - $7.27 Million	30,267 Added 14.3%	241,952 $53.1 Million
Q3 2020 Nov 12, 2020	BUY	$113.26 - $167.27 $3.82 Million - $5.64 Million	33,735 Added 18.96%	211,685 $35.2 Million
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $11.7 Million - $19.6 Million	162,849 Added 1078.4%	177,950 $20.3 Million
Q1 2020 May 13, 2020	BUY	$69.78 - $116.21 $822,147 - $1.37 Million	11,782 Added 354.99%	15,101 $1.16 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $2.49 Million - $4.54 Million	-35,245 Reduced 91.39%	3,319 $428,000
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $4.79 Million - $6.74 Million	-61,480 Reduced 61.45%	38,564 $3.01 Million
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $2.94 Million - $5.18 Million	-49,483 Reduced 33.09%	100,044 $10.3 Million
Q1 2019 May 10, 2019	BUY	$43.65 - $78.95 $3.11 Million - $5.63 Million	71,255 Added 91.04%	149,527 $11 Million
Q4 2018 Feb 13, 2019	SELL	$32.0 - $47.43 $1.35 Million - $1.99 Million	-42,045 Reduced 34.95%	78,272 $3.32 Million
Q3 2018 Nov 13, 2018	BUY	$47.1 - $62.7 $4.06 Million - $5.41 Million	86,218 Added 252.85%	120,317 $5.67 Million
Q2 2018 Aug 10, 2018	BUY	$26.05 - $52.4 $778,243 - $1.57 Million	29,875 Added 707.27%	34,099 $1.68 Million
Q1 2018 May 09, 2018	SELL	$17.2 - $34.95 $109,116 - $221,722	-6,344 Reduced 60.03%	4,224 $130,000
Q4 2017 Feb 14, 2018	SELL	$12.65 - $19.0 $113,862 - $171,019	-9,001 Reduced 46.0%	10,568 $0
Q3 2017 Nov 13, 2017	BUY	$4.7 - $11.7 $91,974 - $228,957	19,569	19,569 $229,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account